-
Mashup Score: 1Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial - 9 month(s) ago
Patients undergoing resection of renal cell carcinoma are at risk of disease relapse. We evaluated the effectiveness of the mammalian target of rapamy…
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0Medical student awarded grant to study lung cancer therapies - 11 month(s) ago
A medical student with a passion for lung cancer research has been awarded the 2023 Daniel T. O’Connor, M.D. Memorial Research Grant.
Source: NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
Proud of my son Matt for receiving this year’s O’Connor grant to study targeted lung cancer therapies https://t.co/dWjyh7WZai
-
-
Mashup Score: 2
(BMS) May 16, 2022 – Bristol Myers Squibb today announced the Phase 3 CheckMate -901 trial, comparing Opdivo (nivolumab) plus Yervoy (ipilimumab) to standard-of-care chemotherapy as a first-line treatment for patients with untreated unresectable or metastatic urothelial carcinoma, did not meet the primary endpoint of overall survival (OS) in patients whose tumor cells express PD-L1 ≥1% at final…
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Checkmate 901 showed that all-IO Nivo/Ipi (2 year duration of therapy) failed to improve OS over standard platinum-based chemo (4-6 cycles GC) in metastatic urothelial cancer with PDL1 >= 1%. Chemo remains a key part of SOC in this subset. https://t.co/pbSssKHOs4 #OBRoncology
-
-
Mashup Score: 0
May 05, 2022 Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New JerseyThis action has been taken out of an abundance of caution as a result of potential quality issues identified in its manufacturing processesThe production suspension impacts commercial and clinical trial supplyCurrent…
Source: NovartisCategories: Hem/Oncs, Latest HeadlinesTweet-
Production issues at Novartis appear to have stymied and delayed radioligand availability, including Pluvicto for PSMA+ CRPC https://t.co/mvka7adwJG
-
-
Mashup Score: 0
(PRINCETON, N.J., SAN FRANCISCO, April 14, 2022) – Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the…
Source: news.bms.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Bristol Myers Squibb - Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) https://t.co/wl12lhl1Ys
-
-
Mashup Score: 2Jonathan W. Riess named medical director of UC Davis Thoracic Oncology Program - The Cancer Letter - 2 year(s) ago
Jonathan Wesley Riess was named medical director of UC Davis Comprehensive Cancer Center’s Thoracic Oncology Program, replacing David R. Gandara, who will soon be co-directing a new center in experimental cancer therapeutics. Riess’ appointment is effective immediately. Riess’ clinical interests include lung cancer and other thoracic cancers (mesothelioma and thymoma). He currently serves on the…
Source: The Cancer LetterCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @TheCancerLetter: Jonathan W. Riess named medical director of @UCD_Cancer Thoracic Oncology Program. https://t.co/Vqxy3DWrtA https://t.c…
-
-
Mashup Score: 1350Login • Instagram - 3 year(s) ago
Welcome back to Instagram. Sign in to check out what your friends, family & interests have been capturing & sharing around the world.
Source: www.instagram.comCategories: Latest Headlines, Oncologists1Tweet-
RT @pickover: The physics of rabbits and other compressible media. https://t.co/jtoxO1fuaB https://t.co/1aTjafXpyc
-
-
Mashup Score: 0
Their Bee Gees cover album ‘Hail Satin!’ arrives next week
Source: SPINCategories: Hem/Oncs, Latest HeadlinesTweet-
@JackWestMD Then check out the Foo Fighters covering BeeGees disco classics on their latest album. They transform into the Dee Gees. ‘You Should Be Dancing' Video https://t.co/cRlFz67r7y
-
-
Mashup Score: 1Allocating Our Protocol Development Resources | SWOG - 3 year(s) ago
Wanting to figure out how to most efficiently allocate protocol development resources across research committees while also providing some resources to research support committees, last December I commissioned a protocol resourcing task force led by SWOG Deputy Chair Dr. Primo “Lucky” Lara. I asked the task force to develop mechanisms for visualizing and allocating statistical and operational…
Source: www.swog.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @SupportingSWOG: The @SWOG Front Line: Allocating Our Protocol Development Resources #SWOGonc https://t.co/ptY3CiPrXT https://t.co/nv5…
-
-
Mashup Score: 2Allocating Our Protocol Development Resources | SWOG - 3 year(s) ago
Wanting to figure out how to most efficiently allocate protocol development resources across research committees while also providing some resources to research support committees, last December I commissioned a protocol resourcing task force led by SWOG Deputy Chair Dr. Primo “Lucky” Lara. I asked the task force to develop mechanisms for visualizing and allocating statistical and operational…
Source: www.swog.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @SWOG: Our @SWOGChair blog A Better Way to Allocate Our Resources for Developing Protocols https://t.co/VadA9iOpQM How to allot protocol…
-
Just published today in the @TheLancet: the results of the @SWOG EVEREST phase 3 trial of adjuvant everolimus vs placebo in completely resected RCC. https://t.co/tNQjHv09zF